GLP-1 Receptor Agonists in Patients with Peptic Ulcer Disease
All GLP-1 receptor agonists are suitable and potentially beneficial for patients with peptic ulcer disease, as recent evidence demonstrates they actually reduce the risk of PUD rather than exacerbate it.
Key Evidence Supporting GLP-1RA Use in PUD
The most recent and highest-quality evidence shows that GLP-1 receptor agonists provide gastrointestinal protective effects, specifically for peptic ulcer disease:
- GLP-1RAs reduce PUD risk by 44-56% compared to other diabetes medications 1, 2
- A 2026 nationwide cohort study of 66,102 patients with type 2 diabetes found GLP-1RA use associated with significantly lower odds of PUD diagnosis (adjusted OR 0.56,95% CI 0.45-0.71) 1
- When used as second-line therapy, GLP-1RAs showed 56% lower hazard of PUD compared to insulin (adjusted HR 0.44,95% CI 0.30-0.63) 1
- A 2025 real-world study of over 2 million patients confirmed GLP-1RAs demonstrated lower risk of peptic ulcer (HR 0.89,95% CI 0.84-0.94) compared to DPP-4 inhibitors 2
All GLP-1RAs Are Appropriate Options
There is no evidence suggesting differential effects among GLP-1 receptor agonists regarding peptic ulcer disease. Available agents include:
- Long-acting weekly agents: Semaglutide, dulaglutide
- Daily agents: Liraglutide, lixisenatide
- Twice-daily agents: Exenatide
- Dual GIP/GLP-1 agonist: Tirzepatide
The choice among these agents should be based on:
- Glycemic control needs
- Cardiovascular or renal comorbidities
- Patient preference for dosing frequency
- Cost and insurance coverage
Critical Caveat: Gastric Emptying Concerns
The primary concern with GLP-1RAs is NOT peptic ulcer exacerbation but rather delayed gastric emptying, which becomes clinically significant during endoscopic or surgical procedures:
- GLP-1RAs increase retained gastric contents during endoscopy by 4-5 fold (OR 4.86-5.24) 3
- This increases pulmonary aspiration risk during procedures (OR 2.29) 3
- Risk persists even in Asian populations (12.2% vs 3.4% retained gastric contents) 4
Peri-Procedural Management Algorithm
For patients requiring endoscopy or surgery while on GLP-1RAs 5, 6:
Continue GLP-1RAs throughout the peri-operative period for patients with diabetes (glycemic and cardiovascular benefits outweigh risks) 5
For weight-loss indication only: Hold for at least 3 half-lives before procedure:
- Semaglutide: 3 weeks
- Dulaglutide: 3 weeks
- Liraglutide: 3-4 days
Risk mitigation strategies 6:
- Point-of-care gastric ultrasound before procedure
- Prokinetic agents (metoclopramide or erythromycin)
- Modified rapid sequence intubation
- Head-up positioning for induction
- Consider regional anesthesia when appropriate
Document specific factors 6:
- Recent dose changes or initiation
- Symptoms of nausea, vomiting, or abdominal distention
- Concomitant medications delaying gastric emptying (opioids, PPIs)
Bottom Line
The presence of peptic ulcer disease is NOT a contraindication to GLP-1RA therapy—in fact, these agents may provide protective benefits against PUD development and recurrence. The real clinical concern is managing delayed gastric emptying during procedures, which requires specific peri-procedural protocols but does not preclude their use in patients with peptic ulcer disease 1, 2, 5.